Page last updated: 2024-10-24

melanocyte apoptotic process

Definition

Target type: biologicalprocess

Any apoptotic process in a melanocyte, the main structural component of the epidermis. [GOC:ic, GOC:TermGenie, PMID:20530876]

Melanocyte apoptosis is a complex, tightly regulated process that involves a series of biochemical and molecular events leading to the programmed death of melanocytes. These events are triggered by a variety of factors, including UV radiation, oxidative stress, and cytotoxic agents.

The process begins with the activation of intracellular signaling pathways, such as the caspase cascade and the mitochondrial apoptotic pathway. Activation of these pathways leads to the breakdown of cellular components, including DNA, proteins, and organelles.

Specifically, the caspase cascade involves a series of proteases that cleave specific proteins, leading to the dismantling of the cell. This process is initiated by the activation of initiator caspases, such as caspase-8 and caspase-9, which then activate effector caspases, such as caspase-3 and caspase-7. These effector caspases cleave a variety of cellular substrates, leading to the characteristic features of apoptosis, such as DNA fragmentation, cell shrinkage, and the formation of apoptotic bodies.

The mitochondrial apoptotic pathway involves the release of cytochrome c from the mitochondria into the cytoplasm. Cytochrome c then binds to the apoptotic protease activating factor 1 (Apaf-1), which activates caspase-9.

These events lead to the morphological changes characteristic of apoptosis, including cell shrinkage, nuclear fragmentation, and the formation of apoptotic bodies. These bodies are then engulfed and degraded by phagocytes, preventing the release of cellular contents into the surrounding tissues.

Melanocyte apoptosis plays a crucial role in maintaining skin homeostasis and preventing the development of skin cancer. However, dysregulation of the apoptotic process can lead to skin disorders such as vitiligo and melanoma. Understanding the molecular mechanisms underlying melanocyte apoptosis is therefore essential for developing effective therapeutic strategies for these diseases.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Prolyl endopeptidase FAPA prolyl endopeptidase FAP that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q12884]Homo sapiens (human)

Compounds (11)

CompoundDefinitionClassesRoles
n-carbobenzoxyglycyl-prolyl-4-methylcoumarinyl amideN-carbobenzoxyglycyl-prolyl-4-methylcoumarinyl amide: fluorogenic substrate for post-proline cleaving enzyme
sitagliptinsitagliptin : A triazolopyrazine that exhibits hypoglycemic activity.triazolopyrazine;
trifluorobenzene
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
environmental contaminant;
hypoglycemic agent;
serine proteinase inhibitor;
xenobiotic
vildagliptinamino acid amide
talabostattalabostat: an antineoplastic agent; structure in first source
linagliptinlinagliptin : A xanthine that is 7H-xanthine bearing (4-methylquinazolin-2-yl)methyl, methyl, but-2-yn-1-yl and 3-aminopiperidin-1-yl substituents at positions 1, 3, 7 and 8 respectively (the R-enantiomer). Used for treatment of type II diabetes.

Linagliptin: A purine and quinazoline derivative that functions as an INCRETIN and DIPEPTIDYL-PEPTIDASE IV INHIBTOR. It is used as a HYPOGLYCEMIC AGENT in the treatment of TYPE II DIABETES MELLITUS.
aminopiperidine;
quinazolines
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
kyp 2047
bms 477118adamantanes;
azabicycloalkane;
monocarboxylic acid amide;
nitrile;
tertiary alcohol
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
alogliptinalogliptin : A piperidine that is 3-methyl-2,4-dioxo-3,4-dihydropyrimidine carrying additional 2-cyanobenzyl and 3-aminopiperidin-1-yl groups at positions 1 and 2 respectively (the R-enantiomer). Used in the form of its benzoate salt for treatment of type 2 diabetes.

alogliptin: structure in first source
nitrile;
piperidines;
primary amino compound;
pyrimidines
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent
gosogliptinamino acid amide
anagliptinanagliptin: anagliptin hydrochloride salt is the active compoundamino acid amide
mk-3102pyrrolopyrazole